This profile hasn't yet passed our validation checks
Submit your email to push it up the queue
Human Genome Sciences Inc.
Human Genome Sciences Inc. (HGS), a pioneering biotechnology firm headquartered in the United States, has been at the forefront of genomic research since its establishment in 1992. With a strong focus on developing innovative therapies for serious diseases, HGS operates primarily in the fields of genomics and biopharmaceuticals. The company is renowned for its unique approach to drug discovery, leveraging genomic data to create targeted treatments. Notable products include Benlysta, a groundbreaking therapy for lupus, which has solidified HGS's position in the biopharmaceutical market. Over the years, HGS has achieved significant milestones, including strategic partnerships and advancements in personalised medicine, further enhancing its reputation as a leader in the industry.
DitchCarbon Score
How does Human Genome Sciences Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Human Genome Sciences Inc.'s score of 100 is higher than 100% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Human Genome Sciences Inc., headquartered in the US, currently does not report any specific carbon emissions data, as indicated by the absence of emissions figures. The company is a current subsidiary of GSK plc, which means that any climate commitments or initiatives may be influenced by GSK's broader sustainability strategies. As part of its corporate family relationship with GSK plc, Human Genome Sciences Inc. may align with GSK's climate initiatives, including targets set under the Science Based Targets initiative (SBTi) and other sustainability frameworks. However, specific reduction targets or achievements for Human Genome Sciences Inc. have not been disclosed. Given the lack of direct emissions data and reduction targets, it is essential to note that the company is likely to follow GSK's commitments to reducing carbon emissions and enhancing sustainability practices. This includes potential participation in initiatives such as the Carbon Disclosure Project (CDP) and RE100, which aim to promote transparency and renewable energy usage. In summary, while Human Genome Sciences Inc. does not provide specific emissions data or reduction targets, its climate commitments may be influenced by the sustainability initiatives of its parent company, GSK plc.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Scope 1 | 851,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 2 | 745,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | 16,093,000,000 | 00,000,000,000 | 00,000,000,000 | 00,000,000,000 | 00,000,000,000 | - | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Human Genome Sciences Inc. is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
